Radiopharmaceutical developer Cerveau Technologies has formed a scientific advisory board made up of chemistry, biology, and medicine experts in Alzheimer's disease.
- Chair: Dr. Serge Gauthier of McGill University in Montreal, Quebec
- Jeffrey Evelhoch, PhD, (retired)
- Dr. Oskar Hansson, PhD, of Lund University in Lund and Skåne University Hospital in Malmö, Sweden
- Richard Hargreaves, PhD, of Bristol Myers Squibb, Lawrenceville, NJ
- Dr. Kanji Ishii, of Tokyo Metropolitan Institute of Gerontology in Japan
- Dr. Keith Johnson of Massachusetts General Hospital and Harvard Medical School in Boston, MA
- Dr. Eric M Reiman of Banner Research in Phoenix, AZ, and the University of Arizona in Tucson, AZ
- Dr. Christopher Rowe of the University of Melbourne, Australia
- Dr. Koen Van Laere, PhD, of University Hospital Leuven-KU in Leuven, Belgium
The new board will support Cerveau's work in developing its tau PET imaging biomarker, MK-6240, the company said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
